Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial
Yuki Obayashi,Masahiro Natsuaki,Hirotoshi Watanabe,Takeshi Morimoto,Ko Yamamoto,Ryusuke Nishikawa,Kenji Ando,Satoru Suwa,Tsuyoshi Isawa,Hiroyuki Takenaka,Tetsuya Ishikawa,Hideo Tokuyama,Hiroki Sakamoto,Takanari Fujita,Mamoru Nanasato,Hideki Okayama,Tenjin Nishikura,Hidekuni Kirigaya,Koji Nishida,Koh Ono,Takeshi Kimura,Kenji Ando,Satoru Suwa,Tsuyoshi Isawa,Hiroyuki Takenaka,Tetsuya Ishikawa,Kohei Wakabayashi,Yuko Onishi,Kiyoshi Hibi,Kazuya Kawai,Koh Ono,Ruka Yoshida,Hiroshi Suzuki,Gaku Nakazawa,Takanori Kusuyama,Itsuro Morishima,Hideo Tokuyama,Hiroki Sakamoto,Takanari Fujita,Mamoru Nanasato,Hideki Okayama,Toshihiro Tamura,Kando Kawahatsu,Fujio Hayashi,Masaharu Akao,Takeshi Serikawa,Kazushige Kadota,Yoshiki Hata,Yoshihiro J Akashi,Shunzo Matsuoka,Hiroyuki Tanaka,Minoru Yamada,Tetsuzo Wakatsuki,Yoichi Nozaki,Yoshio Kobayashi,Ryuichi Kato,Yuji Ikari,Tairo Kurita,Kazuaki Kaitani,Atsuhiko Sugimoto,Nobuhiko Ogata,Takafumi Yokomatsu,Hiroki Uehara,Tatsuki Doijiri,Ken Kozuma,Yasunori Nishida,Junichi Yamaguchi,Yoshihiro Morino,Takashi Tanigawa,Yukiko Nakano,Noriko Makiguchi,Toshiyuki Noda,Nobuo Shiode,Koji Abe,Shichiro Abe,Isao Tabuchi,Shozo Ishihara,Makoto Kinoshita,Motoaki Higuchi,Tomofumi Takaya,Shin-Ichiro Miura,Yoshinori Tsubakimoto,Kenichi Tsujita,Koji Kumagai,Kengo Tanabe,Moriaki Inoko,Takuo Nakagami,Hirofumi Tomita,Masatsugu Nakano,Kazuhiko Yumoto,Takatoshi Wakeyama,Takeo Kaneko,Masayuki Doi,
DOI: https://doi.org/10.1093/ehjcvp/pvae009
2024-01-29
European Heart Journal - Cardiovascular Pharmacotherapy
Abstract:Abstract Background and aims High bleeding risk (HBR) and acute coronary syndrome (ACS) subtypes are critical in determining bleeding and cardiovascular event risk after percutaneous coronary intervention (PCI). Methods and results In 4476 ACS patients enrolled in the STOPDAPT-3, where the no-aspirin and dual antiplatelet therapy (DAPT) strategies after PCI were randomly compared, the pre-specified subgroup analyses were conducted based on HBR/non-HBR and ST-segment elevation myocardial infarction (STEMI)/non-ST-segment elevation ACS (NSTE-ACS). The co-primary bleeding endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5, and the co-primary cardiovascular endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischaemic stroke at 1 month. Irrespective of the subgroups, the effect of no-aspirin compared with DAPT was not significant for the bleeding endpoint (HBR [N = 1803]: 7.27 and 7.91%, hazard ratio (HR) 0.91, 95% confidence interval (CI) 0.65–1.28; non-HBR [N = 2673]: 3.40 and 3.65%, HR 0.93, 95% CI 0.62–1.39; Pinteraction = 0.94; STEMI [N = 2553]: 6.58 and 6.56%, HR 1.00, 95% CI 0.74–1.35; NSTE-ACS [N = 1923]: 2.94 and 3.64%, HR 0.80, 95% CI 0.49–1.32; Pinteraction = 0.45), and for the cardiovascular endpoint (HBR: 7.87 and 5.75%, HR 1.39, 95% CI 0.97–1.99; non-HBR: 2.56 and 2.67%, HR 0.96, 95% CI 0.60–1.53; Pinteraction = 0.22; STEMI: 6.07 and 5.46%, HR 1.11, 95% CI 0.81–1.54; NSTE-ACS: 3.03 and 1.71%, HR 1.78, 95% CI 0.97–3.27; Pinteraction = 0.18). Conclusion In patients with ACS undergoing PCI, the no-aspirin strategy compared with the DAPT strategy failed to reduce major bleeding events irrespective of HBR and ACS subtypes. The numerical excess risk of the no-aspirin strategy relative to the DAPT strategy for cardiovascular events was observed in patients with HBR and in patients with NSTE-ACS.
pharmacology & pharmacy,cardiac & cardiovascular systems